BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kong MY, Li LY, Lou YM, Chi HY, Wu JJ. Chinese herbal medicines for prevention and treatment of colorectal cancer: From molecular mechanisms to potential clinical applications. J Integr Med 2020;18:369-84. [PMID: 32758397 DOI: 10.1016/j.joim.2020.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang HZ, Jiang YL, Yang B, Long FX, Yang Z, Tang DX. Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis. Cancer Med 2022. [PMID: 35650714 DOI: 10.1002/cam4.4896] [Reference Citation Analysis]
2 Jiang X, Jiang Z, Jiang M, Sun Y. Berberine as a Potential Agent for the Treatment of Colorectal Cancer. Front Med 2022;9:886996. [DOI: 10.3389/fmed.2022.886996] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Xia Y, Yang J, Li C, Hao X, Fan H, Zhao Y, Tang J, Wan X, Lian S, Yang J. TMT-Based Quantitative Proteomics Analysis Reveals the Panoramic Pharmacological Molecular Mechanism of β-Elemonic Acid Inhibition of Colorectal Cancer. Front Pharmacol 2022;13:830328. [PMID: 35242040 DOI: 10.3389/fphar.2022.830328] [Reference Citation Analysis]
4 Ge H, Xu C, Chen H, Liu L, Zhang L, Wu C, Lu Y, Yao Q. Traditional Chinese Medicines as Effective Reversals of Epithelial-Mesenchymal Transition Induced-Metastasis of Colorectal Cancer: Molecular Targets and Mechanisms. Front Pharmacol 2022;13:842295. [DOI: 10.3389/fphar.2022.842295] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Han X, Yang C, Guo C, Xu Y, Liu X, Xie R, Meng X, Cheng Z, Fu X. Bioinformatics Analysis to Screen Key Targets of Curcumin against Colorectal Cancer and the Correlation with Tumor-Infiltrating Immune Cells. Evid Based Complement Alternat Med 2021;2021:9132608. [PMID: 34804186 DOI: 10.1155/2021/9132608] [Reference Citation Analysis]
6 Chen F, Lao Z, Zhang H, Wang J, Wang S. Knockdown of circ_0001883 may inhibit epithelial-mesenchymal transition in laryngeal squamous cell carcinoma via the miR-125-5p/PI3K/AKT axis. Exp Ther Med 2021;22:1007. [PMID: 34345289 DOI: 10.3892/etm.2021.10440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Sun Q, He M, Zhang M, Zeng S, Chen L, Zhao H, Yang H, Liu M, Ren S, Xu H. Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery. Front Pharmacol 2021;12:685002. [PMID: 34276374 DOI: 10.3389/fphar.2021.685002] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
8 Feng Y, Jin H, Guo K, Xiang Y, Zhang Y, Du W, Shen M, Ruan S. Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter? Front Pharmacol 2021;12:572845. [PMID: 33716732 DOI: 10.3389/fphar.2021.572845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chang M, Wang H, Niu J, Song Y, Zou Z. Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity. Front Pharmacol 2020;11:610205. [PMID: 33519476 DOI: 10.3389/fphar.2020.610205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]